The objective of the conference and the discussion on reimbursement is to give companies examples of U.S. hands on experience in what is needed to successfully engage and compete in the $100 Billion U.S. medical technology market.
Reimbursement risk and opportunities has become a top-tier issue and important consideration as medical technology companies seek to establish and/or expand in the U.S.
Carla has worked in the field of U.S. healthcare reimbursement, policy, and government relations for over 20 years. Prior to establishing Argenta Advisors and eMgine Health Logics, her career experience included lobbying for a top law firm in Minnesota and providing reimbursement strategy to clients at a large healthcare-consulting firm based in Washington, DC. Carla also worked at the Minnesota Council of Health Plans and has developed and implemented comprehensive reimbursement plans for the U.S. life science sector—medical device, diagnostics, pharmaceuticals, and bio-pharmaceuticals companies.
“My presentation at Medtech in Sweden will provide medical technology companies and their stakeholders a better understanding of how reimbursement affects the ultimate success of a product and it must be fully developed and integrated with regulatory and clinical strategies prior to launch or expansion in the United States,” noted Carla.
eMgine was formed in 2007 by reimbursement consultants with over 30 years working at or with life science companies, commercial plans, Medicare, and. Medicaid. eMgine web-based reimbursement database includes comprehensive Medicare and Medicaid reimbursement policies and payment formulas—which combined is a $900 Billion systems and represents nearly half of the $2 Trillion spent overall in healthcare in the U.S.—that is user friendly and can be customized for the end user.
# # #
For additional information about eMgine Health Logics LLC please visit www.mgine6.com. eMgine web-based reimbursement products—eMcaid and eMcare—are accessible globally anytime and anywhere.